OSM-SMI-8
OSM-SMI-8 is an oncostatin M (OSM) inhibitor with a pKi of 44.82 nM against human targets. OSM-SMI-8 inhibits the activation of STAT3, JNK, ERK 42/44 and AKT signaling pathways induced by OSM. OSM-SMI-8 is applicable to research related to cancer metastasis and Crohn's disease.
For research use only. We do not sell to patients.
- CAS No.: 1689690-20-7
- Formula: C28H20N2O4S2
- Molecular Weight:512.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Cancer cell lines | IC50 |
531 nM
|
Inhibition of OSM-induced activity in cancer cells assessed via absorbance measurement at 540 nm after treatment with OSM (5 ng/mL) and varying concentrations of OSM-SMI-8.
Inhibition of OSM-induced activity in cancer cells assessed via absorbance measurement at 540 nm after treatment with OSM (5 ng/mL) and varying concentrations of OSM-SMI-8.
|
en?oq=US9550828B2 |
In Vitro
OSM-SMI-8 inhibits OSM-induced detachment of prostate cancer cells[2].
OSM-SMI-8 inhibits OSM-induced pSTAT3 activation in cancer cells[2].
OSM-SMI-8 (531 μM; 30 min) inhibits the OSM-induced activation of STAT3, JNK, ERK 42/44 and AKT signaling pathways in MDA-MB-231 cells[2].
OSM-SMI-8 (2.44-2500 nM; 30 min) potently inhibits OSM-induced activity, with an IC50 of 531 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 cells
-
Concentration:531 μM
-
Incubation Time:30 min
-
Result:Inhibited OSM-induced activation of STAT3, JNK, ERK 42/44, and AKT signaling pathways.
-
Cell Line:MDA-MB-231 cells
-
Concentration:2.44, 9.77, 39.06, 156.25, 625, 2500 nM
-
Incubation Time:30 min
-
Result:Inhibited OSM-induced activity.
Chemical Information
-
CAS No. 1689690-20-7
-
Molecular Weight 512.60
-
Formula C28H20N2O4S2
-
SMILES
OC(/C(C1=CSC(C2=NC(/C(C(O)=O)=C/C=C/C3=CC=CC=C3)=CS2)=N1)=C\C=C\C4=CC=CC=C4)=O
-
Synonyms
NSC642624
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)